MC32 tumor cells acquire Ag-specific CTL resistance through the loss of CEA in a colon cancer model

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 8, 2015, Pages 2012-2020

  Lee, Sang Yeul ^a   Sin, Jeong Im ^a  

^a Kangwon National University   (South Korea)

Author keywords

Antitumor immunity; CEA; Colon cancer; DNA vaccines; Immune evasion

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; DNA VACCINE; GAMMA INTERFERON; GENOMIC DNA; LACTATE DEHYDROGENASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; COLON CANCER; CONTROLLED STUDY; DNA PURIFICATION; FEMALE; FLOW CYTOMETRY; IMMUNOCOMPETENT CELL; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TUMOR VOLUME; VACCINATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; COLON TUMOR; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DISEASE MODEL; GENETICS; IMMUNE EVASION; IMMUNOLOGY; NEOPLASM;

ANIMALS; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FEMALE; IMMUNE EVASION; MICE, INBRED C57BL; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84944458932     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1016669     Document Type: Article

References (31)

1. Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006; 93:1115-22; PMID:16804870; http://dx. doi. org/10. 1002/bjs. 5349
2. Thompson J, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991; 5:344- 66; PMID:1941355; http://dx. doi. org/10. 1002/jcla. 1860050510
3. Hara M, Sato M, Takahashi H, Takayama S, Takeyama H. Accuracy of monitoring serum carcinoembryonic antigen levels in postoperative stage III colorectal cancer patients is limited to only the first postoperative year. Surg Today 2011; 41:1357-60; PMID:21922357; http://dx. doi. org/10. 1007/s00595- 010-4519-2
4. Wang WS, Lin JK, Chiou TJ, Liu JH, Fan FS, Yen CC, Lin TC, Jiang JK, Yang SH, WangHS, ChenPM. Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn J Clin Oncol 2000; 30:12-6; PMID:10770562; http://dx. doi. org/10. 1093/jjco/hyd003
5. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigenvaccinia virus vaccine. J Natl Cancer Inst 1992; 84:1084-91; PMID:1619682; http://dx. doi. org/ 10. 1093/jnci/84. 14. 1084
6. Hodge J. Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol Immunother 1996; 43:127-34; PMID:9001565; http://dx. doi. org/ 10. 1007/s002620050313
7. Kim SG, Park MY, Kim CH, Sohn HJ, Kim HS, Park JS, Kim HJ, Oh ST, Kim TG. Modification of CEA with both CRT and TAT PTD induces potent antitumor immune responses in RNA-pulsed DC vaccination. Vaccine 2008; 26:6433-40; PMID:18812201; http://dx. doi. org/10. 1016/j. vaccine. 2008. 08. 072
8. Park JS, Kim HS, Park HM, Kim CH, Kim TG. Efficient induction of anti-tumor immunity by a TAT-CEA fusion protein vaccine with poly(I:C) in a murine colorectal tumor model. Vaccine 2011; 29:8642-8; PMID:21945963; http://dx. doi. org/10. 1016/j. vaccine. 2011. 09. 052
9. Ahn E, Kim H, Han KT, Sin JI. A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Ag-specific CTLs in a colon cancer model. Cancer Lett 2015; 356:676-85; PMID:25449428; http://dx. doi. org/10. 1016/j. canlet. 2014. 10. 019
10. Song K, Chang Y, Prud'homme GJ. IL-12 plasmidenhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice. Gene Ther 2000; 7:1527-35; PMID:11021590; http://dx. doi. org/10. 1038/sj. gt. 3301274
11. Song K, Chang Y, Prud'homme GJ. Regulation of Thelper- 1 vs. T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer. Gene Ther 2000; 7:481-92; PMID:10757021; http://dx. doi. org/ 10. 1038/sj. gt. 3301123
12. Conforti A, Peruzzi D, Giannetti P, Biondo A, Ciliberto G, La Monica N, Aurisicchio L. A novel mouse model for evaluation and prediction of HLA-A2- restricted CEA cancer vaccine responses. J Immunother 2009; 32:744-54; PMID:19561534; http://dx. doi. org/ 10. 1097/CJI. 0b013e3181aee1b6
13. Facciabene A, Aurisicchio L, Elia L, Palombo F, Mennuni C, Ciliberto G, La Monica N. Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects. Vaccine 2007; 26:47- 58; PMID:18055074; http://dx. doi. org/10. 1016/j. vaccine. 2007. 10. 060
14. Mennuni C, Calvaruso F, Facciabene A, Aurisicchio L, Storto M, Scarselli E, Ciliberto G, La Monica N. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer 2005; 117:444-55; PMID:15906358; http://dx. doi. org/10. 1002/ijc. 21188
15. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002; 71:907-20; PMID:12050175
16. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-b signaling in T cells. Nat Med 2001; 7:1118- 22; PMID:11590434; http://dx. doi. org/10. 1038/ nm1001-1118
17. Thomas DA, Massagué J. TGF-b directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer cell 2005; 8:369-80; PMID:16286245; http://dx. doi. org/10. 1016/j. ccr. 2005. 10. 012
18. Urban JL, Kripke ML, Schreiber HJ. Stepwise immunological selection of antigenic variants during tumor growth. J Immunol 1986; 137:3036-41; PMID:3489784
19. Bai XF, Liu J, Li O, Zheng P, Liu Y. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest 2003; 111:1487-96; PMID:12750398; http://dx. doi. org/10. 1172/ JCI17656
20. Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 1999; 190:1033-8; PMID:10510093; http://dx. doi. org/ 10. 1084/jem. 190. 7. 1033
21. Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA, Franken KL, Hahne M, Albar JP, Melief CJ, Offringa R. Blockade of the granzyme B/ perforin pathway through overexpression of the serine protease inhibitor PtdIns-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 2001; 98:11515-20; PMID:11562487; http://dx. doi. org/10. 1073/pnas. 201398198
22. Jazirehi AR, Baritaki S, Koya RC, Bonavida B, Economou JS. Molecular mechanism of MART-1+/ A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Res 2011; 71:1406-17; PMID:21159666; http://dx. doi. org/10. 1158/0008-5472. CAN-10-1296
23. Kim H, Kwon B, Sin JI. Combined stimulation of IL-2 and 4-1BB receptors augments the antitumor activity of E7 DNA vaccines by increasing Ag-specific CTL responses. PLoS One 2013; 8:e83765; PMID:24391824; http://dx. doi. org/10. 1371/journal. pone. 0083765
24. Sin JI, Kim H, Ahn E, Jeon YH, Park WS, Lee SY, Kwon B. Combined stimulation of TLR9 and 4. 1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTLs and their infiltration into tumor sites. Cancer Lett 2013; 330:190-9; PMID:23219755; http://dx. doi. org/10. 1016/j. canlet. 2012. 11. 045
25. Noh KH, Lee YH, Jeon JH, Kang TH, Mao CP, Wu TC, Kim TW. Cancer vaccination drives Nanogdependent evolution of tumor cells toward an immuneresistant and stem-like phenotype. Cancer Res 2012; 72:1717-27; PMID:22337995; http://dx. doi. org/ 10. 1158/0008-5472. CAN-11-3758
26. Aurisicchio L, Peruzzi D, Koo G, Wei WZ, La Monica N, Ciliberto G. Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models. Hum Gene Ther 2014; 25:121-31; PMID:24195644; http://dx. doi. org/10. 1089/hum. 2013. 103
27. Diaz-Montero CM, Chiappori A, Aurisicchio L, Bagchi A, Clark J, Dubey S, Fridman A, Fabregas JC, Marshall J, Scarselli E, La Monica N, Ciliberto G, Montero AJ. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med 2013; 11:62; PMID:23497415; http://dx. doi. org/10. 1186/1479-5876-11-62
28. Sin JI, Sung JH, Suh YS, Lee AH, Chung JH, Sung YC. Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of co-injection with a granulocyte, macrophage-colony stimulating factor gene. Vaccine 1997; 15:1827-33; PMID:9413089; http://dx. doi. org/10. 1016/S0264-410X(97)88856-1
29. Bae SH, Park YJ, Park JB, Choi YS, Kim MS, Sin JI. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatintreated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res 2007; 13:341-9; PMID:17200373; http://dx. doi. org/10. 1158/1078- 0432. CCR-06-1838
30. Ye GW, Park JB, Park YJ, Choi YS, Sin JI. Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic antitumor activity. Mol Ther 2007; 15:1564-70; PMID:17505485; http://dx. doi. org/ 10. 1038/sj. mt. 6300149
31. 180-188 peptides. Cancer Immunol Immunother 2012; 61:1671-82; PMID:22382361; http://dx. doi. org/ 10. 1007/s00262-012-1214-8